Ads
related to: tecfidera cost- View Savings and Support
Learn More About Patient Access
and Other Support Options
- Whisperject Instructions
How To Use Glatiramer Acetate
WhisperJECT Autoinjector
- GA Mechanism of Action
Learn More About How
Glatiramer Acetate Works
- GA Efficacy and Safety
Review Glatiramer Acetate
Efficacy and Safety Information
- View Savings and Support
Search results
Biogen holds onto Tecfidera market in Europe for a little longer
BioPharma Dive via Yahoo Finance· 5 months agoA decision by European regulators to revoke approvals for five generic versions of Biogen's multiple...
Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have lost about...
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
Zacks via Yahoo Finance· 4 months agoBiogen BIIB reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.95, which missed...
Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?
Zacks via Yahoo Finance· 6 months agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have added about...
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
Zacks via Yahoo Finance· 2 years agoBiogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat...
Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue
Investor's Business Daily· 4 months agoBiogen's turnaround is still a "work in progress," an analyst said Tuesday as Biogen stock slumped...
Biogen tops 3Q expectations as cost cutting continues
Associated Press via Yahoo News· 2 years agoBiogen delivered a better-than-expected third quarter and hiked its 2022 forecast, as cost cutting...
Biogen fourth-quarter profit misses on Aduhelm exit costs
Reuters via AOL· 4 months agoLast month, Biogen said it will end a post-approval study of Aduhelm and return the licensing rights...
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
Zacks via Yahoo Finance· 1 year agoBiogen BIIB reported first-quarter 2023 adjusted earnings per share (EPS) of $3.40, beating the...
Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout
Investor's Business Daily· 7 months agoBiogen stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But...
Ads
related to: tecfidera cost
